Geode Capital Management LLC Boosts Holdings in Pharvaris (NASDAQ:PHVS)

Geode Capital Management LLC raised its stake in shares of Pharvaris (NASDAQ:PHVS) by 18.4% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 36,977 shares of the company’s stock after buying an additional 5,753 shares during the period. Geode Capital Management LLC owned about 0.12% of Pharvaris worth $685,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Novo Holdings A S grew its holdings in Pharvaris by 47.7% during the second quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock worth $32,430,000 after acquiring an additional 556,970 shares during the period. Deerfield Management Company L.P. Series C grew its stake in shares of Pharvaris by 31.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock worth $26,269,000 after purchasing an additional 335,687 shares during the period. Sofinnova Investments Inc. grew its stake in shares of Pharvaris by 2.9% during the 2nd quarter. Sofinnova Investments Inc. now owns 601,534 shares of the company’s stock worth $11,309,000 after purchasing an additional 16,862 shares during the period. Sphera Funds Management LTD. increased its holdings in shares of Pharvaris by 8.9% during the 3rd quarter. Sphera Funds Management LTD. now owns 439,292 shares of the company’s stock valued at $8,136,000 after purchasing an additional 36,027 shares in the last quarter. Finally, Patient Square Capital LP acquired a new position in shares of Pharvaris in the 3rd quarter valued at $4,488,000.

Pharvaris Stock Performance

Shares of NASDAQ PHVS opened at $17.80 on Friday. The company has a market capitalization of $566.75 million, a PE ratio of -6.36 and a beta of -3.06. The company’s fifty day moving average price is $20.12 and its 200 day moving average price is $19.35. Pharvaris has a 1 year low of $15.37 and a 1 year high of $33.00.

Pharvaris Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.